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Abstract
Introduction: Determining how primary pharmaceutical as-
sistance is structured allows us to establish situational diag-
noses and to visualize possible implications for an essential 
part of the Brazilian Unified Health System. Methods: We 
evaluated pharmaceutical services of all municipalities that 
compose the Regional Inter-Agency Committee on Health of 
Ourinhos-São Paulo (CIR-Ourinhos-SP) through structure, 
process, and outcome indicators, and, in a shared way, we 
proposed actions to qualify the practice. We conducted di-
rect observations of drugs, records, documents, interviews 
with pharmacists, and visits to health care centers, totaling 
12 municipalities, 41 health care centers, and 3 pharmaceuti-
cal supply services. Results: In the thematic workshop car-
ried out with municipal representatives, we found that 
68.33% of health care centers and 70% of pharmaceutical 
supply services met good storage practices. We verified an 
average of 0.85 pharmacists per unit and the presence of 
88.91% of marker drugs. Workshop proposals were sent to 
managers and pharmacists responsible for pharmaceutical 
assistance of 12 municipalities. Conclusions: Most indicators 
were below the established standards, demonstrating the 
need for adjustments in the infrastructure and provision of 
training for professionals.
© 2019 The Author(s). Published by S. Karger AG, Basel 
on behalf of NOVA National School of Public Health
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Resumo
Introdução: A apuração de como as Assistências Farma-
cêuticas Básicas (AFB) municipais estão estruturadas per-
mite o delineamento do diagnóstico situacional e visual-
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ização de possíveis implicações em parte essencial do 
Sistema Único de Saúde. Métodos: Avaliamos as AFB de 
todos os municípios que compõem a Comissão Interges-
tores Regional de Saúde de Ourinhos-SP (CIR-Ourinhos-
SP), por meio de indicadores de estrutura, processo e re-
sultado, e propôs-se, de forma compartilhada, ações para 
qualificar a prática. Foram realizadas observações diretas 
em medicamentos, cadastros, documentos, entrevistas 
com farmacêuticos, visitas às unidades de saúde (US), per-
fazendo 12 municípios, 41 US e 03 Centrais de Abastec-
imento Farmacêutico (CAF). Resultados: Na oficina 
temática realizada com os representantes municipais ver-
ificou-se, entre outras coisas, que 68,33% das US e 70% 
das CAF, cumpriam as boas práticas de armazenamento. 
Foi encontrada a média de 0,85 farmacêutico por unidade 
e presença de 88,91% de medicamentos marcadores. As 
propostas da Oficina foram encaminhadas aos gestores e 
farmacêuticos responsáveis pelas AFB dos 12 municípios. 
Conclusões: A maioria dos indicadores ficou abaixo dos 
padrões estabelecidos, demonstrando a necessidade de 
adequações na infraestrutura e de oferta de capacitações 
para as os profissionais.
© 2019 The Author(s). Published by S. Karger AG, Basel 
on behalf of NOVA National School of Public Health
Introduction
The importance of pharmaceutical assistance in the 
Brazilian Unified Health System (Sistema Único de 
Saúde – SUS) is due to the promotion of users’ access to 
drugs and supplies and the role of these services in tech-
nological innovation and development and rational 
drug use [1]. Therefore, verifying how municipal pri-
mary pharmaceutical assistance is structured in organi-
zational terms, infrastructure, and human resources al-
lows us to establish situational diagnoses and to visual-
ize possible implications for an essential part of the SUS, 
namely Primary Health Care. 
Health policy in Brazil is organized through a single 
integrated and universal system, the SUS, established by 
the 1988 Constitution and legitimized by Law No. 
8080/90, presenting characteristics of decentralization, 
regionalization, and social participation. The SUS is 
structured through health care networks, which aim to 
provide systemic integration, actions, and health care ser-
vices with continuous, integral, and humanized assis-
tance, distributed in their health care locations based on 
different technological densities, from low (Primary 
Health Care) and intermediate (Secondary Health Care) 
densities to higher density (Tertiary Health Care). In the 
SUS, the role of intergovernmental administration is ful-
filled by Inter-Agency Committees: Bipartite (CIB), Re-
gional (CIR), and Tripartite (CIT) [2, 3].
Integral therapeutic care, including pharmaceutical 
care, is defined in Law No. 8080/90 as one of the actions 
to be performed by the SUS [4]. Decentralization and 
strengthening of pharmaceutical assistance were marked 
by the extinction of the Medicines Center (former Central 
de Medicamentos – CEME) in 1997 [5] and later with the 
National Policy of Pharmaceutical Assistance in 2004 [6]. 
Primary pharmaceutical assistance encompasses all these 
aspects, involving a level of specific health care, whose 
drugs are present in the Primary Component of Pharma-
ceutical Assistance (Componente Básico de Assistência 
Farmacêutica – CBAF) [7].
In order for these aspects to be efficiently carried out 
in Primary Health Care, evaluation must be a constant 
focus of management, to the extent that it is present in 
legislation and documents, such as in Administrative 
Rule No. 1555/13, which regulates the application of fi-
nancial resources and their implementation in the CBAF 
within the scope of the SUS, establishing the mandatory 
presentation of the Annual Management Report for fol-
low-up, monitoring, and evaluation of the application of 
financial resources transferred between the health care 
funds [8]. The evaluation process also meets the strategies 
of the World Health Organization (WHO) when, for ex-
ample, evaluating the availability of essential drugs 
through indicators of ensured access. 
Donabedian [9] proposed an operational didactic provi-
sion of indicators for evaluating health care services at three 
levels: structure, process, and outcome. The technical lit-
erature in the field [10, 11] and several studies on the eval-
uation of pharmaceutical assistance have laid foundations 
in this sense [12–14]; those related to structure provide in-
formation on the quality of the basic structures, which can 
be verified within each key component, and are used to as-
sist in the formulation of strategies and for planning inter-
ventions to improve the pharmaceutical assistance; those 
related to process inform the mechanisms and activities of 
the pharmaceutical assistance policies and supervise some 
aspects such as: selection of essential drugs, allocation of 
drugs within the health care budget and the financing sec-
tor policy, procedures for hiring, distribution, logistics, and 
information and continuing education on rational drug 
use, as well as those related to outcome measure – whether 
these objectives are being achieved [15].
Health care evaluation, however, does not make sense 
if the outcomes are not discussed and analyzed, prefera-
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bly by the actors involved in the evaluated service or ac-
tivity. This participatory and shared mechanism is essen-
tial to achieve relevant outcomes to the studied reality [16, 
17]. Our study evaluated the pharmaceutical assistance of 
Primary Health Care in municipalities that compose the 
Regional Inter-Agency Committee on Health of 
Ourinhos-São Paulo (CIR-Ourinhos-SP), through struc-
ture, process, and outcome indicators, and proposed, in a 
participatory manner, interventions for providing the as-
sistance together with local workers and managers, based 
on our findings.
Materials and Methods
A pretest was performed, and information was subsequently 
collected through specific indicators to compose an initial situa-
tional diagnosis. Subsequently, a thematic workshop was held in-
volving the 12 municipalities that compose the CIR-Ourinhos-SP, 
belonging to one of the seventeen Regional Departments of Health 
(Departamento Regional de Saúde – DRS) of the State Secretariat 
of Health of São Paulo/SP (Secretaria de Estado da Saúde – SES/
SP), as we can observe in the flowchart (Fig. 1). In the state of São 
Paulo, the administrative division of SES/SP is done through the 
DRS, and these are subdivided into Regional Inter-Agency Com-
mittees (CIR), such as CIR-Ourinhos-SP, belonging to the DRS-
IX, responsible for coordinating activities of the State Secretariat 
of Health at the regional level and for promoting intersector ar-
ticulation between municipalities and civil-society organizations.
The selection of the study site was based on the position of the 
studied region in the Social Responsibility Index of São Paulo 
(Índice Paulista de Responsabilidade Social – IPRS) [18], selecting 
a region that presented more than 50% of the municipalities with 
low levels of income and intermediate levels of longevity and/or 
education and the most disadvantaged regions of the state, con-
cerning both income and social indicators. This index is used in 
the state of São Paulo, Brazil, according to the Human Develop-
ment Index (HDI), which may allow us to compare parameters 
in future studies, within all geographical limitations and socio-
economic differences that exist in a continental country such as 
Brazil.
For the outcome indicators R3, R4, R5, R6, R7, and R8 (Table 1), 
1,230 prescriptions were selected, with 30 prescriptions in each of 
the 41 studied health care units. This number was based on a previ-
ous study by Rieck [11]. Such selection was carried out by system-
atic random sampling, with concealment of the names of the pa-
tients present in the unit during the last 5 days prior to the visit. In 
cases in which the number of prescriptions was unfeasible, the pre-
scriptions from subsequent previous days were selected, up to the 
number of 30 prescriptions.
Inclusion and Exclusion Criteria
All Primary Health Care Units that comprise the CIR-
Ourinhos-SP, which dispensed the drugs part of the CBAF, were 
included in the study. In the case of prescriptions, those originat-
ing from any institution other than Primary Health Care Units 
were excluded, as well as those identified as unreadable by the re-
searcher and/or unsigned and/or without identification of the le-
gally qualified prescriber. 
Drugs considered available were those present in prescriptions 
and that provided some type of dispensing identification. Prescrip-
tions retained by the health care centers that contained only one 
drug prescribed without health care identification were deemed 
available. The drug was considered prescribed by the generic name 
when its nomenclature was in agreement with the Brazilian Com-
mon Denomination (BCD). Prescriptions recorded with a brand 
name were accepted when the generic name was also properly 
written. Prescriptions with generic names were accepted when in-
correctly written and/or abbreviated, provided they were clearly 
identified by the researcher and had no registered trademark with 
their abbreviation, such as AAS®. Existing nomenclatures in the 
Brazilian List of Essential Medicines (Relação Nacional de Medica­
mentos Essenciais – RENAME) and those generally accepted were 
also considered, such as oral rehydration salts, mineral oil, and 
zinc paste.
In the case of herbal medicines, we considered the synonymy 
or the popular nomenclature according to the Form of Herbal 
Medicines of the Brazilian Pharmacopoeia [19] or Board Resolu-
tion No. 95/08 [20].
Description of the Indicators
Indicators were identified, according to WHO criteria, in order 
to provide the following information:
 − Indicators of Structure (En): information on the quality of basic 
structures of pharmaceutical care
- Selection of a municipality of the
 DRS-IX, not belonging to 
 CIR-Ourinhos-SP, with at least 1 unit 
 for dispensing medicines of the PHC
Pretest
- Indicators of structure, process, and
 outcome
- 12 municipalities/41 health care units
 of the CIR-Ourinhos-SP with 
 dispensing of medicines of the PHC













Fig. 1. Flowchart of the implementation of research for evaluating 
pharmaceutical assistance in health care units of the Primary 
Health Care (PHC), through the collection of information by spe-
cific indicators in municipalities that compose the Regional Inter-
Agency Committee of Ourinhos-SP (CIR-Ourinhos-SP).
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 − Indicators of Process (Pn): information on the mechanisms and 
activities of the pharmaceutical care policy 
 − Indicators of Outcome (Rn): information on achieving objec-
tives of pharmaceutical care policy, availability of and accessi-
bility to essential drugs, quality, and rational use
Thematic Workshop
After data collection, a thematic workshop was held with the 
present municipalities of the CIR-Ourinhos-SP, mainly focused 
on those responsible for the municipal pharmaceutical assistance. 
Objectives of the study, results of the survey, and description of the 
script for conducting the study were presented. There were three 
groups of four members each, and 80 min to discuss the collected 
data, reporting causes, proposals, and challenges for facing/im-
proving them, with the presence of the mediator/researcher in 
each group, in a successive way, stimulating discussions without, 
however, interfering with the proposals. This was followed by a 
60-min plenary session, in which the proposals of each group were 
presented. The workshop had a total duration of 5 h, with enough 
space for each group to discuss and list the proposals. Primary 
pharmaceutical assistance was specially addressed, focusing on the 
results found in the initial survey of indicators in order to analyze 
such results, discuss possible causal factors, and develop strategies 
in a participatory and collaborative manner. 
Table 1. Identification of used indicators
Indicators Description Utility Desired value
Structure E1 Number of pharmacists working in US Points to one of the aspects of the policy on AF 1/for each US.
E2 Training/retraining of AF professionals Quantitatively evaluates the provided events by verifying 
the workers’ qualification
50% of the AF employees 
with at least 1 
participation/year in 
training programs
E3 Compliance with Good Storage Practices 
in the municipal areas for storage of 
medicines (CAF and US)
Evaluates the storage, since inappropriate procedures can 
lead to shortages and loss of medicines and resources
100%
E4 Number of US that comprise REMUME 
at a visible location all users of the system
Contributes to the promotion of the Rational Use of 
Medicines (Uso Racional de Medicamentos – URM), 
enabling resource optimization and expanding the access
80%
Process P1 Existence of inventory control of 
medicines in municipal areas of storage 
of medicines (CAF and US)
Supports the programming and acquisition, avoiding 
superimposition of inventories and/or shortages, 
guaranteeing regularity and waste
100%
Outcome R1 Availability of marker drugs1 in the US Evaluates the availability of access, of users of the system, 
to essential medicines
80%
R2 Percentage of outdated medicines in the 
US
Ensures safety, efficacy, and quality of drugs, promotion 
of URM, and access
0%
R3 Average number of prescribed drugs in 
the US
Contributes to formulate and develop strategies for URM 2 medications or less  
per prescription
R4 Percentage of primary medicines in 
Annex I of RENAME 2012 (CBAF) 
prescribed in the US
Establishes the knowledge and acceptance of the 
prescribers, supply credibility, and quality in promoting 
health care 
70%
R5 Number of drugs prescribed by BCD 
and/or ICD in the US
Acquisition and prescription by BCD comprise legal 
devices that aim to reduce costs, ensuring quality, 
effectiveness, and safety of medicines
100%
R6 Percentage of items of drugs prescribed 
and available in the US
Evaluates the access of SUS users to prescribed drugs 80%
R7 Percentage of prescriptions fully met for 
SUS users in the US
Evaluates the complete access of users to the prescribed 
drugs, and, therefore, the effectiveness of the AF steps
60%
R8 Percentage of medicines in Annex I of 
RENAME 2012 (CBAF) prescribed and 
available in the US
Determines the availability of CBAF medicines and, 
therefore, the access
95%
Source: Adapted from Rieck [11], WHO [15] and Cosendey [34]. AF, Pharmaceutical Assistance; CAF, Pharmaceutical Supply Centers; US, Health Care 
Unit of the Primary Health Care (PHC); REMUME, Municipal List of Essential Medicines; RENAME, Brazilian List of Essential Medicines; CBAF, Primary 
Component of Pharmaceutical Assistance; CBD, Brazilian Common Denomination; ICD, International Common Denomination; URM, Rational Use of 
Medicines. 
1 Marker drugs, also known as tracer or index drugs, or basket of drugs. These aim to lower costs and streamline the research. The selected medicines 
must be part of the national list of essential medicines, be among the most important and most used medicines from the therapeutic point of view, have low 
cost per unit, and preferably be internationally available in order to enable comparisons [29]. The number of listed drugs may be between 10 and 50 (WHO 
[15]); 20 (Islam [30]); and between 25 and 50 drugs (RPM [31]). In the National Survey on Access, Use and Promotion of Rational Use of Medicines in Bra-
zil (Pesquisa Nacional sobre Acesso, Utilização e Promoção do Uso Racional de Medicamentos no Brasil – PNAUM), 58 drugs were deemed key medicines 
(Brasil [27]), and in our study we selected 20 medicines.
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Results
In Table 2 we show the results for each indicator in 
their respective municipalities, regional average, and 
comparative standards, according to the literature. The 
municipalities were identified by twelve capital letters 
(from A to L) without logical order.
The E3 Indicator of Structure and the P1 Indicator of 
Process apply both to Pharmaceutical Supply Centers 
(Centrais de Abastecimento Farmacêuticos – CAF) and to 
Health Care Units (Unidades de Saúde – US), in such a 
way they are identified as E3-US, E3-CAF, P1-US, and 
P1-CAF. The thematic workshop was attended by repre-
sentatives from 7 of the 12 municipalities (58.3%) that 
compose the CIR-Ourinhos-SP. Specific aspects were dis-
cussed in each indicator, and in Table 3 we present the 
current and consolidated proposals.
Discussion
The novelty of this study is in the creation of local and 
regional proposals through a participative and democrat-
ic process based on the observed situational reality, aim-
ing to achieve goals validated by the literature.
The major debate during the workshop on pharma-
ceutical assistance conducted in this study concerned the 
responsibility of the pharmaceutical professionals and 
the importance of their actions in the resolution of ther-
apeutic treatments. One of the first collective findings 
was that municipalities need to hire more pharmacists, 
since the number of pharmacists found in the primary 
pharmaceutical assistance of the CIR-Ourinhos-SP was 
below the standard of at least one professional per each 
dispensing unit [21]. In 2005, Naves and Silver [22] 
showed outcomes even less significant in the Federal Dis-
trict, with 0.13 professionals per US. Bernardi et al. [12], 
when evaluating 20 municipalities of Rio Grande do Sul 
state, according to the primary pharmaceutical assis-
tance evaluation, found 0.25 professionals per US. How-
ever, Menolli et al. [23] and Freitas and Nobre [14] found 
no pharmacist in 10 health care centers in the munici-
palities of Londrina (in Paraná state) and Mombaça (in 
Ceará state). As reported by Naves and Silver [22], drugs 
that act on the central nervous system, included in ordi-
nance No. 344/98 [5], are not dispensed in the absence of 
a professional in the center, which was also observed in 
our study. This does not preclude access to essential 
drugs for mental health; however, it can excessively hin-
der it.
In addition, with regard to work management, the 
number of pharmaceutical assistance workers who par-
ticipated in trainings in the 12 months prior the survey 
was lower than the standard set by Rieck [11], which is at 
least 50%. However, Freitas and Nobre [14], in a study 
conducted in a municipality of Ceará state, reported that 
there was no training program for pharmaceutical assis-
tance employees. The Brazilian legislation on health care 
is clear as to the need for the development and training of 
human resources. According to Law No. 8.080/90, train-
ing and continuing education comprise a coordinated in-
tersector action, defining the creation of a permanent 
Table 2. Indicators of structure (E), process (P), and outcome (R) of each municipality of the CIR-Ourinhos-SP that dispenses drugs for 
basic health care, regional average, and standards
Municipality E1 E2 E3-HC E3-PSS E4 P1-HC P1-PSS R1 R2 R3 R4 R5 R6 R7 R8
A 0.67 16.67 56.67 60.00 33.33 0.00 0.00 81.67 6.67 1.69 67.11 75.00 30.26 50.00 41.18
B 1.00 0.00 40.00 40.00 0.00 0.00 0.00 85.00 0.00 1.27 52.63 63.16 100.00 100.00 100.00
C 1.00 0.00 80.00 70.00 0.00 100.00 0.00 100.00 0.00 2.47 62.16 83.78 85.14 76.67 89.13
D 1.00 16.67 90.00 90.00 0.00 100.00 100.00 80.00 0.00 2.38 73.36 82.71 78.04 71.11 80.89
E 1.00 0.00 80.00 80.00 0.00 100.00 100.00 100.00 0.00 2.03 49.18 75.41 85.25 80.00 96.67
F 0.67 0.00 76.67 80.00 0.00 100.00 100.00 83.33 16.67 1.97 63.28 83.05 88.14 82.22 92.86
G 1.00 0.00 60.00 50.00 0.00 100.00 100.00 95.00 0.00 1.63 83.67 97.96 100.00 100.00 100.00
H 1.00 0.00 50.00 60.00 0.00 0.00 100.00 80.00 10.00 2.30 71.01 86.96 68.12 60.00 65.31
I 0.33 14.29 66.67 70.00 0.00 66.67 100.00 100.00 10.00 1.89 57.06 72.35 85.29 81.11 94.85
J 1.00 100.00 70.00 70.00 0.00 100.00 100.00 80.00 0.00 1.63 51.02 91.84 30.61 50.00 28.00
K 0.25 12.50 55.63 80.00 0.00 0.00 100.00 81.88 1.88 2.29 71.55 77.82 59.82 47.50 70.52
L 1.29 17.39 94.29 90.00 0.00 100.00 100.00 100.00 0.00 2.39 65.67 72.46 88.62 84.29 95.74
Average regional 0.85 14.79 68.33 70.00 2.78 63.89 75.00 88.91 3.77 1.99 63.98 80.21 74.94 73.57 79.59
Standard1 1.00 50.00 100.00 100.00 80.00 100.00 100.00 80.00 0.00 2.00 70.00 100.00 80.00 60.00 95.00
CIR-Ourinhos-SP, Regional Inter-Agency Committee on Health of Ourinhos-São Paulo; HC, Health Care Services; PSS, Pharmaceutical Supply Services.
1 Standards according to the literature (Rieck [11]). E1 = Number of pharmacists working in the BPS. E2 = Training of PS workers. E3 = Compliance with Good Storage Practices in municipal areas of drug 
storage (PSS and HC). E4 = Number of HC that have REMUME in visible location to all healthcare system users. P1 = Existence of drug inventory control in municipal areas of drug storage (PSS and HC). R1 = 
Availability of marker drugs in the HC. R2 = Percentage of expired drugs in the HC. R3 = Average number of drugs per prescription in the HC. R4 = Percentage of basic drugs in Annex I of RENAME 2012 (CBAF) 
prescribed in the HC. R5 = Number of drugs prescribed by BCD and/or INN in the HC. R6 = Percentage of items of drugs prescribed and served in the HC. R7 = Percentage of prescriptions completely served to 
UHS users in the HC. R8 = Percentage of drugs of Annex I of RENAME 2012 (CBAF) prescribed and available in the HC.
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Table 3. Proposals listed during the thematic workshop on basic pharmaceutical services of the CIR-Ourinhos-
SP, based on the proposed indicators
Indicator Proposals
E1 Awareness of managers to hire at least 1 pharmacist per drug dispensing unit, according to the legislation in 
force
E2 Development of project together with the Continuing Education Center (NEPER, in Portuguese) to conduct a 
Workshop on Pharmaceutical Services;
Internal meetings with the team;
Possibility of videoconference on Pharmaceutical Services in the CIR-Ourinhos-SP;
Awareness of managers on the importance and need of training for the Pharmaceutical Services team
E3 Improvement in conditions of physical structures and materials of pharmacies;
Adequate weatherization and cooling;
Development of a regional Good Storage Practices guideline (concise), based on the legislation in force
E4 Revise the Municipal List of Essential Medicines (REMUME) based on the legislation in force;
Awareness of managers as to the users’ right of access to the list of essential medicines in a visible place
P1 Computerization with specific, integrated software, and staff training;
Need to acquire computer equipment and human resources
R1 Maintaining regular acquisition of drugs of the Basic Pharmaceutical Services (BPS);
Development of protocol with criteria for dispensation of free drugs by the People’s Pharmacy Program, aiming 
at actual guarantee of access 
R2 Computerization;
Implementation of pharmaceutical supervision;
Training of servants;
Insertion, maintenance, and verification of the terms of the tender notice as to the requirement for the expiry 
date of the drugs to be delivered 
R3 Awareness and interaction with the prescriber 
R4 Awareness and interaction with the prescriber 
R5 Awareness and interaction with the prescriber;
Disclosure of the standardized list and knowledge of the legislation
R6 Awareness and interaction with the prescriber; 
Maintenance and regulation of the stock of drugs;
Compliance with Decree No 7.508/11;
Periodic revision of REMUME according to the Brazilian List of Essential Medicines (RENAME);
Improvement in the data of information of service of dispensed medicines;
Implementation of dispensing stamp with minimal identification of the Health Center and dispenser, date of 
service and dispensed quantity
R7 Awareness and interaction with the prescriber; 
Maintenance and regulation of the stock of drugs;
Periodic revise of REMUME according to RENAME;
Improvement in the data of information of service of dispensed medicines;
Implementation of dispensing stamp with minimal identification of the Health Center and dispenser, date of 
service and dispensed quantity
R8 Awareness and interaction with the prescriber; 
Maintenance and regulation of the stock of drugs;
Compliance with Decree No 7.508/11;
Periodic revise of REMUME according to RENAME;
Improvement in the data of information of service of dispensed medicines;
Development of protocol with criteria for dispensation of free drugs by the People’s Pharmacy Program, aiming 
at actual guarantee to access;
Implementation of dispensing stamp with minimal identification of the Health Center and dispenser, date of 
service and dispensed quantity
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committee of integration between health care services 
and vocational and higher education institutions [4]. 
Training and development of human resources is the 
guideline of the National Drug Policy (Política Nacional 
de Medicamentos), and the development, enhancement, 
appreciation, establishment, and training of human re-
sources [6, 24] is one of the strategic priorities of the Na-
tional Pharmaceutical Assistance Policy (Política Nacio­
nal de Assistência Farmacêutica). Thus, the development 
of projects and even immediate practical actions to pro-
mote training in the field of Pharmaceutical Assistance is 
paramount. Therefore, during the workshop, through 
analysis and discussion of these outcomes, we proposed 
the formation of a study group with pharmaceutical pro-
fessionals of the CIR-Ourinhos-SP.
Regarding the indicator that deals with the proper 
storage of drugs (E3), of the ten checked items, no mu-
nicipality met the goal of 100%. Barreto and Guimarães 
[25], in a study on municipalities in the state of Bahia, 
detected the absence of physical and environmental con-
ditions for the storage of drugs as well as inadequate 
transportation and absence of the pharmacist in dispens-
ing. These factors can lead to loss of drugs due to being 
expired, resulting in a waste of resources and in access to 
drugs of dubious quality.
A pharmaceutical supply services evaluation study 
carried out in Brazil in 2004 by the Pan American Health 
Organization (PAHO) [26] showed overall averages of 
61.1% of items met by the health care centers, lower than 
that found in our study, and 70.1% by the pharmaceutical 
supply services, virtually identical to the values we ob-
tained.
Regarding good storage practices, in our study, as well 
as in the studies by Bernardi et al. [12] and Freitas and 
Nobre [14], we established the same indicator (E3). How-
ever, to determine it, it is necessary to verify various items 
and these items have no standardization, in such a way 
that the cited studies analyzed several items, although 
they assessed the same indicator proposed in our study, 
considering that the checklist for verifying good storage 
practices is not far from the ultimate goals of the evalua-
tion. It is noteworthy that in our study we did not use the 
same checklist as PAHO [26] and Barreto and Guimarães 
[25], which can be considered a limiting factor. There-
fore, in addition to standardization of indicators, we sug-
gest the standardization of items to be deemed indispens-
able. 
Concerning the indicator of structure related to the 
Municipal List of Essential Medicines (Relação Municipal 
de Medicamentos Essenciais – REMUME), established in 
a visible location to users (E4 indicator), only one health 
care center of CIR-Ourinhos-SP was in compliance. In a 
study on pharmaceutical assistance evaluation in Brazil 
[26], and in Londrina, in Paraná state, by Menolli et al. 
[23], 70% of the US had a list of drugs, but did not describe 
whether they were visible and/or available to users. The 
same occurred in the National Survey on Access, Use and 
Promotion of Rational Use of Medicines in Brazil (Pes­
quisa Nacional sobre Acesso, Utilização e Promoção do 
Uso Racional de Medicamentos no Brasil – PNAUM), ac-
cording to which 85.9% of the municipalities presented a 
standardized list, and its access by the municipality is 
available in most units (77.6%), followed by pharmacies 
(65%) and the municipal department of health (51.3%) 
[27].
According to Rieck [11], such is an indicator of politi-
cal dimension and that gives users information about the 
stage of their treatment. The reasons for this nondisclo-
sure of the standardization may reflect difficulty or con-
cern of the pharmaceutical care regarding failure to main-
tain a correct supply of drugs in health care centers, both 
due to management problems and to scarcity of budget-
ary and financial resources. Nevertheless, this could hin-
der the implementation of programming and purchasing 
of drugs.
The inventory control in health care centers and 
pharmaceutical supply centers was below that estab-
lished in the literature, which is 100%, but slightly above 
the 32% of inventory records for health care centers, 
32% in municipal pharmaceutical supply services, and 
61% in state pharmaceutical supply services, found in 
the study by PAHO [26]. Barreto and Guimarães [25] 
detected a lack of inventory control in 2 municipalities 
in Bahia, Brazil, and Freitas and Nobre [14] found 100% 
inventory control in a study in a municipality in Ceará, 
Brazil, which was manual in health care centers and 
computerized in pharmaceutical supply centers. How-
ever, da Silva [28] found manual inventory control at 
first and, after the pharmacist arrived, this process be-
came computerized, suggesting pharmaceutical care 
improvement through operational and managerial mea-
sures. Our study reflects the perceived need of support 
on the part of management for effective inventory con-
trol, preferably computerized.
Determining marker drugs is important for collecting 
indicators. These drugs should be on the National List of 
Essential Drugs, be among the most used drugs, have low 
cost per unit, and preferably have international availabil-
ity [15, 29]. The number of listed drugs may be between 
10 and 50 according to the WHO [15], 20 according to a 
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guideline published by Islam [30], and between 25 and 50 
drugs according to the Rational Pharmaceutical Manage-
ment Project [31]. In the PNAUM, 58 were deemed key 
medicines, including herbal medicines [27].
We found rates higher than those found by Menolli et 
al. [23] in a study conducted in Londrina (80%), by Mou-
ra and Perini [32], in Minas Gerais (74%), and by Freitas 
and Nobre [14], in Ceará (70%). According to the Pri-
mary Health Care of the SUS, the physical availability of 
essential drugs verified in the PNAUM only accounted 
for 52.9% [27].
The value of the indicator could be even higher than 
that, since marker drugs, which are part of the CBAF and 
part of the list of drugs distributed free of charge by the 
Popular Pharmacy Program (Programa Farmácia Popu­
lar) of the Brazilian Ministry of Health [33], were not in 
the stock of health care centers of some municipalities we 
studied. The statement from those in charge of municipal 
pharmaceutical assistance was that these drugs would be 
available to users at pharmacies accredited by the gov-
ernment program. This should be further discussed, 
since, as mentioned previously, not dispensing drugs in 
health care centers may not prevent but can sometimes 
hinder access. Therefore, besides the need for regular ac-
quisition of drugs directed to primary pharmaceutical as-
sistance, during the workshop the preparation of proto-
cols with the establishment of criteria for dispensing, or 
not dispensing, drugs by the Popular Pharmacy Program 
was discussed, thus aiming to ensure the access needed. 
Since we found a higher index than the established stan-
dard [11] and than several studies in the literature, the 
provision of important drugs for therapeutic resolution 
in Primary Health Care in that specific region is deemed 
satisfactory. Some factors are certainly positively inter-
fering, such as the mechanism for automatic and regular 
transfer of funds, provision of drugs through the state 
program, bidding processes for price record (thus de-
creasing the cost and streamlining their acquisition), and 
mandatory allocation of federal funds received with mu-
nicipal counterpart. A limiting factor in the collection of 
this indicator may be the choice of the drugs determined 
as markers. 
According to the R2 indicator of outcome, the ideal 
standard is having no expired drugs [11, 34]. In health 
care centers of the CIR-Ourinhos-SP there were expired 
drugs available, higher than the 2% found in the state of 
Rio Grande do Sul [12] and in the study on the evaluation 
of pharmaceutical assistance in Brazil [26], whose au-
thors found 0.3% of drugs in this situation. However, 
Freitas and Nobre [14], in a study in Mombaça (in Ceará 
state), found 18.75% of expired drugs, but in a secluded 
space not exposed to users, which is still a risk factor, and 
which shows potential problems in management. Ex-
pired drugs refer to issues related to safety, therapeutic 
efficacy, and potential problems in the management and 
infrastructure of pharmaceutical assistance. During the 
collection of this indicator, we observed drugs whose ex-
piry date could not be identified and more than one man-
ufacturing lot of the product in the same container, avail-
able for dispensing, which may cause loss, risk to the 
users’ health and, once again, may indicate potential 
problems in management and infrastructure. This indi-
cator was very much discussed during the course of the 
workshop, since it can be directly related to the training 
of servants that support the dispensing in pharmacies in 
the US, and also to the responsibility of pharmacists. 
Therefore, proper monitoring of the responsible people 
has been suggested concerning drug fractioning, separa-
tion of different lots of drugs in the dispensing area, and 
training courses for employees of the pharmaceutical as-
sistance field. 
The average of prescribed drugs per prescription unit 
(R3) is an indicator suggested by the WHO. The average 
of more than two drugs may reflect problems in the pre-
scribing practice [15]. According to Bernardi et al. [12], 
prescribing fewer drugs per appointments in Primary 
Health Care, whose main objective is based on the pro-
motion and prevention of health, may represent a ratio-
nal use of drugs, even with the possible aforementioned 
variations. 
Certainly, there are socioeconomic, cultural, and tem-
poral variables, among others, that may affect these com-
parisons. In Brazil, Cosendey [34] found an average of 
2.11 drugs per prescription in a multicenter study con-
ducted in five Brazilian states. Authors of other studies on 
different regions of the country found values ranging 
from 2.0 to 2.4 [12, 14, 22, 23, 26, 29, 35, 36]. We found 
the value of 1.9, and therefore it is more favorable than 
other national results, except for that found by Colombo 
et al. [37] in Blumenau (in Santa Catarina state), which 
accounted for an average of 1.8 drugs per prescription. 
The indicator of outcome related to the prescribed 
drugs part of the CBAF of RENAME 2012 (R4) was below 
the standard level of 70% [11, 34], but higher than that 
found by Colombo et al. [37], based on RENAME, which 
accounted for 57.7%. This indicator shows proper selec-
tion, standardization, and adherence of the prescriber to 
the List of Essential Drugs. The PAHO evaluation of 
pharmaceutical assistance in Brazil in 2005 showed an av-
erage of 78.3% of prescribed drugs present in RENAME, 
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despite the large variation found in the 30 surveyed ser-
vices, from 48.4 to 97.4%.
In several studies, this indicator was verified based on 
lists of local drugs with different names: Local List of Es-
sential Drugs (Lista Local de Medicamentos Essenciais –
LLME), by Cunha [35], finding 92.7% of the prescribed 
drugs present in it; Municipal List of Essential Medicines 
(REMUME), by Marcondes [29], 87%; List of Standard-
ized Drugs (Lista de Medicamentos Padronizados – LMP), 
by Santos and Nitrini [36], 83.4%; List of Essential Drugs, 
by Naves and Silver [22], 85.3%; List of Primary Drugs 
(Relação de Medicamentos Básicos – REMEB), by Bernar-
di et al. [12], 76%; and finally, the List of Essential Drugs, 
by Menolli et al. [23], accounting for 73%.
Note that all studies based on standardized lists of local 
drugs obtained rates higher than our study and the estab-
lished standard of 70%, which can demonstrate high ad-
herence to standardized drugs, a selection complying 
with technical criteria or, in fact, standardization based 
on the prescribers’ demand. 
There may be standardization in the survey regarding 
this indicator, considering RENAME and more specifi-
cally drugs of the CBAF, as in the case of studies on Pri-
mary Health Care. More actions must be promoted to 
increase this index, that is, to improve the adherence of 
prescribers to the standardized list of essential drugs. 
These actions involve the technical expertise of pharma-
cists and their capacity to coordinate with prescribers, 
which was discussed and agreed during the workshop.
In the SUS, prescriptions should be written by gener-
ic name, following the Brazilian Common Denomina-
tion (BCD) or the International Common Denomina-
tion (ICD), according to legislation [38, 39]. In prescrip-
tions researched in health care centers of 
CIR-Ourinhos-SP, the value found was higher than that 
of 69.42% found by Cosendey [34] in a research conduct-
ed in five Brazilian states; that of 71% found by Mar-
condes [29]; that of 30.6%, by Santos and Nitrini [36]; 
that of 73.2%, by Naves and Silver [22]; that of 64%, by 
Bernardi et al. [12]; and that of 66.5%, by Menolli et al. 
[23]. However, the values were lower compared with 
those found by Cunha et al. [35], 84.3%; PAHO [26], 
84.2% (varying from 69.2 to 97.4%); and Freitas and No-
bre [14], accounting for 91%. 
da Silva [28] reported an increase in prescriptions by 
generic names from 56.54% in 2003, without the pharma-
cist, to 75.6% in 2004 after the presence of the pharmacist, 
suggesting that the influence of the professional’s work 
would improve the prescription by the nomenclature rec-
ommended in the legislation. In a study conducted in 
Brazil on Access, Use and Promotion of Rational Use of 
Medicines (PNAUM), 59.6% of physicians reported that 
they always use BCD or the generic name to prescribe 
drugs to patients; 31.6% use it sometimes, and 8.8% say 
they do not use it [27]. Therefore, we observed that al-
though the value found is below the established standard 
of 100%, encouraged by the existence of the specific leg-
islation, the index was higher than those of many studies 
in the literature.
In the field research of our study, we perceived that 
long generic names induce the prescription of brand 
names, which generally tend to be less extensive. One ex-
ample was the drug used as a contraceptive, whose ge-
neric name is Ethinyl estradiol 0.03 mg + levonorgestrel 
0.15 mg, usually prescribed in the US with the brand 
name Ciclo 21®, which is not always the brand or drug 
present for dispensing, but whose name is undeniably 
shorter and easier to remember.
The criteria used by the researchers in the consider-
ation and characterization of the generic nomenclature 
can also interfere with the collection of this indicator, 
such as the acceptance or nonacceptance of prescrip-
tions with generic names in the form of abbreviations, 
such as HCT (hydrochlorothiazide), which is easily 
identified by the pharmacist and accepted, but noncom-
pliant with the law.
In the workshop we discussed not only compliance 
with legislation, but also awareness, interaction with pre-
scribers, and possible alternatives to be addressed, such as 
the aforementioned acronyms of generic names usually 
practiced. Would that be more reasonable than the brand-
named prescription? This issue should be widely dis-
cussed by pharmaceutical professionals, since it is not a 
straightforward decision. It involves legal prerogatives. 
The population’s ensured access to primary essential 
drugs is one of the guidelines of the National Drug Policy 
[24], and therefore verifying prescribed and available 
drugs is of extreme importance.
The R6 and R7 indicators – respectively, the percent-
age of prescribed and available drugs in the US – were 
lower than the values found by Bernardi et al. [12] in Rio 
Grande do Sul, which accounted for 88% for prescribed 
and available drugs, and 84% for prescriptions complete-
ly given. In contrast, Marcondes [29] described 60% for 
prescribed and dispensed drugs. Of three countries that 
had percentage data of drug dispensing (Bangladesh, Ni-
geria, and Nepal) in a study conducted by Hogerzeil et al. 
[40], two of them had indicators above 80% (Bangladesh 
and Nepal). A study by Cosendey [34] showed an average 
of 95% of prescribed and available drugs, ranging from 
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63.37% in Acre state to 100% in the state of Goiás. Good 
rates achieved by the CIR-Ourinhos-SP, although a little 
below the standard of 80% for prescribed and available 
drugs, especially if compared with the values obtained in 
Brazil, may demonstrate adequate adherence of prescrib-
ers to the list of standardized drugs. This may result from 
the pharmacists’ work or even from regional characteris-
tics, such as the small population size of most of the stud-
ied municipalities, which may facilitate stock manage-
ment. 
It is worth noting our limitation in collecting data of 
the R6, R7, and R8 outcome indicators, because of the ab-
sence of some sort of dispensing identification. For fur-
ther discussion on access to drug in Primary Health Care, 
we included the R8 outcome indicator, which refers to the 
percentage of prescribed and available CBAF drugs, that 
is, the capacity of health care centers in providing essen-
tial drugs at this level of health care. The index obtained 
for drugs belonging to the CBAF of RENAME, prescribed 
and available in the health care centers of CIR-Ourinhos-
SP, was below the established standard, which is 95% [34], 
but higher than 74.94% when considering all prescribed 
drugs.
The CBAF service is a municipal obligation according 
to Decree No. 1554/2013 [41] of the Brazilian Ministry of 
Health; therefore, this indicator should be close to 100%. 
Failure to comply with this indicator may point to non-
adherence of the prescriber to the standardized list of 
drugs, poor selection of these drugs, and problems in the 
programming and purchasing of these products.
In the survey on PNAUM, 59.8% of users reported full 
access to Primary Health Care medicines in the SUS. The 
Southeast Region, where CIR-Ourinhos-SP is included, 
had a higher percentage (64.3%), and the lowest was in 
the Midwest Region (46.3%); 36% of users reported par-
tial access, and less than 5% reported not having access to 
medicines in the SUS dispensing units [27].
The thematic workshop was positive, even with the ab-
sence of some municipalities. The discussion held by 
those in the workshop, in addition to enabling the assess-
ment of the local pharmaceutical assistance, provided the 
development of measures for improvement of the pre-
sented indicators. 
Our results are unprecedented within the field of re-
gional pharmaceutical assistance, since all primary phar-
maceutical assistance of municipalities that compose the 
CIR-Ourinhos-SP were assessed, through the collection 
of indicators established and recommended by the litera-
ture, and also by preparing, in a democratic and partici-
pative manner, an intervention proposal for the practice 
of the assistance. Thus, we could collect and discuss, in a 
participative way, indicators of an area of public health 
that grows and improves, but which still has problems 
related to structural and organizational aspects and pro-
fessional training at the municipal level.
We recommend that the intervention proposal be im-
plemented, monitored, and evaluated. Therefore, form-
ing a study group for pharmaceutical assistance of the 
CIR-Ourinhos-SP would be an important aspect in this 
process.
We should mention that in 2012 the Brazilian Ministry 
of Health created the National Qualification Program of 
Pharmaceutical Assistance within the SUS (Programa 
Nacional de Qualificação da Assistência Farmacêutica no 
âmbito do Sistema Único de Saúde – QUALIFAR-SUS), 
whose purpose was to contribute to the process of im-
provement, implementation, and integration of pharma-
ceutical assistance, both in actions and in health care ser-
vices [42, 43]. Qualification steps were carried out be-
tween 2012 and 2014, and between 2017 and 2018, and 1 
municipality of CIR-Ourinhos-SP was on the list of mu-
nicipalities that qualified in 2014, and 4 in 2018 [43].
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